The Role of Non-Coding RNAs in Epigenetic Dysregulation in Glioblastoma Development.
Ekaterina IsacheskuCornelia BraicuRadu PîrlogAnja KocijancicConstantin BusuiocLavinia-Lorena PruteanuDeo Prakash PandeyIoana Berindan NeagoePublished in: International journal of molecular sciences (2023)
Glioblastoma (GBM) is a primary brain tumor arising from glial cells. The tumor is highly aggressive, the reason for which it has become the deadliest brain tumor type with the poorest prognosis. Like other cancers, it compromises molecular alteration on genetic and epigenetic levels. Epigenetics refers to changes in gene expression or cellular phenotype without the occurrence of any genetic mutations or DNA sequence alterations in the driver tumor-related genes. These epigenetic changes are reversible, making them convenient targets in cancer therapy. Therefore, we aim to review critical epigenetic dysregulation processes in glioblastoma. We will highlight the significant affected tumor-related pathways and their outcomes, such as regulation of cell cycle progression, cell growth, apoptosis, angiogenesis, cell invasiveness, immune evasion, or acquirement of drug resistance. Examples of molecular changes induced by epigenetic modifications, such as DNA epigenetic alterations, histone post-translational modifications (PTMs), and non-coding RNA (ncRNA) regulation, are highlighted. As understanding the role of epigenetic regulators and underlying molecular mechanisms in the overall pro-tumorigenic landscape of glioblastoma is essential, this literature study will provide valuable insights for establishing the prognostic or diagnostic value of various non-coding transcripts, including miRNAs.
Keyphrases
- dna methylation
- gene expression
- cell cycle
- genome wide
- cancer therapy
- systematic review
- cell proliferation
- single molecule
- risk assessment
- cell free
- drug delivery
- cell cycle arrest
- copy number
- induced apoptosis
- stem cells
- cell death
- type diabetes
- endoplasmic reticulum stress
- adipose tissue
- cell therapy
- skeletal muscle
- nucleic acid
- spinal cord injury